ANDA 204159, held by Apotex. Temozolomide.
As of Nov 16, 2026, ANDA 204159 (Temozolomide), held by Apotex, was first approved by FDA on Jul 5, 2018, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 5, 2018 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide20MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide100MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide140MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide180MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide250MG · capsule;oral | Temozolomide | Discontinued |
| May 16, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 22, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters